INVO Bioscience, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading symbol: INVO) on September 12, 2020. The report addresses corporate governance changes, specifically the departure of two directors and the appointment of two new directors to the Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the restructuring of the Board of Directors:
- Resignations: Kathleen Karloff and Michael Campbell resigned as directors on September 12, 2020. The filing states these resignations were not due to any disagreements with the Company regarding operations, policies, or practices.
- Continued Employment: Michael Campbell will continue to serve as Chief Operating Officer and Vice President of Business Development.
- Appointments: Matthew Szot was appointed as a director on September 13, 2020, and Barbara Ryan was appointed on September 14, 2020, to fill the vacancies.
Management Commentary and New Director Profiles
Management highlighted the qualifications of the new appointees:
- Matthew Szot: Currently Executive Vice President and CFO of S&W Seed Company (Nasdaq: SANW). He brings expertise in M&A, corporate strategy, financings, and SEC reporting. He is also a CPA and currently serves on the board of SenesTech (Nasdaq: SNES).
- Barbara Ryan: Founder of Barbara Ryan Advisors with over 30 years of experience as a sell-side research analyst covering the US Large Cap Pharmaceutical Industry. She previously served as a Managing Director at Deutsche Bank/Alex Brown and has deep experience in life sciences equity and debt financings.
Key Facts for Investor Verification
- Verify the effective dates of the new director appointments (September 13 and 14, 2020) and their tenure terms.
- Confirm that Michael Campbell remains employed as COO and VP of Business Development despite his resignation from the Board.
- Review the Company's subsequent filings to assess the impact of these governance changes on strategic direction.
- Note that this filing contains no financial data; refer to the most recent 10-K or 10-Q for financial performance.